http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2694843-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_707fed4a1a60fa61a1abd576112d5c64
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
filingDate 2018-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2019-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe008f497c9b58747a557ad155c0d23e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5aee9ccae65b4418136d2b2da79737e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cce5db89e87aa61b5f2c62108ec3b2ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06bf9dfb91d5c3440cc72043aef00173
publicationDate 2019-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2694843-C1
titleOfInvention METHOD FOR PREDICTING THE COURSE OF A PATHOLOGICAL PROCESS IN LUMINAL NON-HYPEREXPRESSION OF Her2Neu PRIMARY OPERABLE BREAST CANCER IN POSTMENOPAUSAL WOMEN
abstract FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to oncology, and can be used in predicting the course of a pathological process in luminal non-hyperexpression of Her2neu primary operable breast cancer in postmenopausal women. That is ensured by determining the androgen receptor expression level in the immunohistochemical examination of the tumor tissue. If observing androgens at 0–4 % and 5–20 %, the aggressive course of luminal Her2neu non-hyperexpression of primary operable breast cancer is predicted.EFFECT: invention allows predicting the course of luminal non-hyperexpression of Her2neu of primary operable breast cancer in postmenopausal women depending on the level of androgen receptor expression that promotes individual treatment of this category of patients.1 cl, 3 ex
priorityDate 2018-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2632112-C1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID374
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID2232
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID100005148
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID317748
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID134688829
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID11997
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID29183
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID737737
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433323226
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID367
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID55378
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID13075
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID403588
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID100009122
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID24208
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID14149
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID11835
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID24192
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID231
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID692587
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID280675
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID396816
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID36203
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID79122
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID44503
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID55378
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID14187
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID11839
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID747460
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID11677
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID100689318
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID422165

Total number of triples: 48.